
    
      Current treatment for non-small cell lung cancer (NSCLC) remains inadequate. Vorinostat is a
      novel agent that inhibits the enzymatic activity of histone deacetylases (HDACs). Bortezomib
      is a small molecule proteasome inhibitor. Preclinical and clinical studies have shown the
      advantages of combining these two agents in the treatment of NSCLC
    
  